Preliminary results of a Phase I trial of LOXO-292, report high response rates for patients with RET fusion proteins (∼69%) and also suggest some effect on brain metastases, a key challenge in managing NSCLC (Drilon et al., 2018b,c; Subbiah et al., 2018c). The gene discussed is RET; the disease is non-small cell lung carcinoma.